Zealand Pharma Shares Jump Ahead of Major ADA Data Presentations
Zealand Pharma shares climbed sharply as investors positioned for full data releases at the American Diabetes Association's 2026 Scientific Sessions and on fresh analyst moves. Key Phase 3 and Phase 2 results, plus a price-target revision from Deutsche Bank and continued support from Jefferies, underpinned the rally even as U.S. equity indices fell…